Details of the Drug Combination

General Information of Drug Combination (ID: DC9QRYC)

Drug Combination Name
GDC-0152 Rabeprazole
Indication
Disease Entry Status REF
Amyotrophic Lateral Sclerosis Phase 1 [1]
Component Drugs GDC-0152   DM1B3UM Rabeprazole   DMMZXIW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of GDC-0152
Disease Entry ICD 11 Status REF
Obesity 5B81 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [3]
GDC-0152 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
X-linked inhibitor of apoptosis protein (XIAP) TTR7B60 XIAP_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Indication(s) of Rabeprazole
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [4]
Gastrinoma 2C10.1 Approved [5]
Peptic ulcer DA61 Approved [5]
Rabeprazole Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Gastric H(+)/K(+) ATPase alpha (ATP4A) TTF1QVM ATP4A_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Rabeprazole Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Rabeprazole Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [8]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02655614) A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
2 Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13.
3 Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7290).
5 Rabeprazole FDA Label
6 Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:17-23.
7 Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9.
8 Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603.